JCXH-221

· Immorna Biotherapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JCXH-221, covering 2024-09-19 to 2024-09-19. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine [Phase 1]

See pricing